Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma

被引：47

作者：

Porrata, Luis F. ^{[1
]}

Ristow, Kay ^{[1
]}

Habermann, Thomas M. ^{[1
]}

Ozsan, Nazan ^{[3
]}

Dogan, Ahmet ^{[2
]}

Macon, William ^{[2
]}

Colgan, Joseph P. ^{[1
]}

Witzig, Thomas E. ^{[1
]}

Inwards, David J. ^{[1
]}

Ansell, Stephen M. ^{[1
]}

Micallef, Ivana N. ^{[1
]}

Johnston, Patrick B. ^{[1
]}

Nowakowski, Grzegorz S. ^{[1
]}

Thompson, Carrie ^{[1
]}

Markovic, Svetomir N. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Dept Med, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA

[3] Ege Univ, Dept Pathol, Izmir, Turkey

来源：

LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 11期

关键词：

Lymphoma and Hodgkin disease; survival; monocyte/lymphocyte prognostic score; NON-HODGKINS-LYMPHOMA; RITUXIMAB ERA; EXPRESSION; CHEMOTHERAPY; IMMUNOCHEMOTHERAPY; SUBTYPES; MODELS; TUMOR; CHOP;

D O I：

10.3109/10428194.2012.690605

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The absolute monocyte/lymphocyte count prognostic score (AMC/ALC score) has not been directly compared with the cell of origin (COO) to predict overall survival (OS) and progression-free survival (PFS) in diffuse large B-cell lymphoma (DLBCL). Thus, we retrospectively examined a new cohort of 99 patients with DLBCL treated from 2008 to 2010, (1) to validate whether AMC/ALC score affects survival, (2) to investigate whether AMC/ALC score is independent of COO to predict survival and (3) to assess whether AMC/ALC score can further stratify clinical outcomes by COO. By univariate analysis, the AMC/ALC score was a predictor for OS and PFS. On multivariate analysis performed including the COO and the International Prognostic Index, AMC/ALC score remained an independent predictor for OS and PFS. The AMC/ALC score was able to further stratify DLBCL clinical outcomes by COO. The AMC/ALC score was independent of COO and added to its ability to identify patients with high-risk disease.

引用

页码：2159 / 2165

页数：7

共 25 条

[21] Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab [J].

Oki, Yasuhiro ;

Yamamoto, Kazuhito ;

Kato, Harumi ;

Kuwatsuka, Yachiyo ;

Taji, Hirofumi ;

Kagami, Yoshitoyo ;

Morishima, Yasuo .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (06) :448-453

[22] Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning [J].

Shipp, MA ;

Ross, KN ;

Tamayo, P ;

Weng, AP ;

Kutok, JL ;

Aguiar, RCT ;

Gaasenbeek, M ;

Angelo, M ;

Reich, M ;

Pinkus, GS ;

Ray, TS ;

Koval, MA ;

Last, KW ;

Norton, A ;

Lister, TA ;

Mesirov, J ;

Neuberg, DS ;

Lander, ES ;

Aster, JC ;

Golub, TR .

NATURE MEDICINE, 2002, 8 (01) :68-74

[23] Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy [J].

Song, M. -K. ;

Chung, J. -S. ;

Seol, Y. -M. ;

Kim, S. -G. ;

Shin, H. -J. ;

Choi, Y. -J. ;

Cho, G. -J. ;

Shin, D. -H. .

ANNALS OF ONCOLOGY, 2010, 21 (01) :140-144

[24] The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma [J].

Wilcox, R. A. ;

Ristow, K. ;

Habermann, T. M. ;

Inwards, D. J. ;

Micallef, I. N. M. ;

Johnston, P. B. ;

Colgan, J. P. ;

Nowakowski, G. S. ;

Ansell, S. M. ;

Witzig, T. E. ;

Markovic, S. N. ;

Porrata, L. .

LEUKEMIA, 2011, 25 (09) :1502-1509

[25] Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells [J].

Wilcox, Ryan A. ;

Wada, David A. ;

Ziesmer, Steven C. ;

Elsawa, Sherine F. ;

Comfere, Nneka I. ;

Dietz, Allan B. ;

Novak, Anne J. ;

Witzig, Thomas E. ;

Feldman, Andrew L. ;

Pittelkow, Mark R. ;

Ansell, Stephen M. .

BLOOD, 2009, 114 (14) :2936-2944

← 1 2 3 →